20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Opko Health, Inc. (NASDAQ:OPK) shares are trading higher Wednesday after the FDA approved NGENLA treatment for pediatric growth hormone deficiency, produced in partnership with Pfizer (NYSE:PFE).
What To Know: The approval was suppoerted by results from a multi-center, randomized, open-label, active-controlled Phase 3 study evaluating the safety and efficacy of NGENLA when administered once-weekly compared to once-daily somatropin.
"Throughout our collaboration with Pfizer, we have worked tirelessly toward our shared goal of helping children living with growth hormone disease and their families," said Phillip Frost, Chairman and CEO, OPKO Health.
"We are proud of the clinical development program that supported the FDA approval of NGENLA and are excited about its potential for these patients and their families as it becomes available in the United States."
The once-weekly, human growth hormone analog is expected to become available for U.S. prescribing in August 2023 and is already approved for the treatment of pediatric GHD in more than 40 markets.
Related Link: Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
OPK Price Action: Shares of OPK were up 1.81% at $1.69 at the time of publication, according to Benzinga Pro.
Image by PublicDomainPictures from Pixabay
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!